Pipeline

Commercialized Products

TAVALISSE® (fostamatinib)1

Adult Chronic Immune Thrombocytopenia
Target: Spleen tyrosine kinase (SYK)

Pre-Clinical Phase 1 Phase 2 REGISTRATIONAL Approved
Pre-Clinical Complete
Phase 1 Complete
Phase 2 Complete
REGISTRATIONAL Complete
Approved Complete

REZLIDHIA® (olutasidenib)2

R/R mIDH1 Acute Myeloid Leukemia
Target: Mutant isocitrate dehydrogenase–1 (mIDH1)

Pre-clinical Phase 1 Phase 2 REGISTRATIONAL Approved
Pre-clinical Complete
Phase 1 Complete
Phase 2 Complete
REGISTRATIONAL Complete
Approved Complete

GAVRETO® (pralsetinib)3

RET+ Non-Small Cell Lung Cancer & Advanced Thyroid Cancer
Target: Rearranged During Transfection (RET)

Pre-clinical Phase 1 Phase 2 REGISTRATIONAL Approved
Pre-clinical Complete
Phase 1 Complete
Phase 2 Complete
REGISTRATIONAL Complete
Approved Complete

In-Licensed Program

VEPPANUTM (vepdegestrant)4

ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
Target: Estrogen receptor (ER) degradation via PROTAC (PROteolysis-TArgeting Chimera)

Pre-clinical Phase 1 Phase 2 REGISTRATIONAL Approved
Pre-clinical Complete
Phase 1 Complete
Phase 2 Complete
REGISTRATIONAL Complete
Approved Complete

Clinical Programs

R289*

Lower-Risk Myelodysplastic Syndrome
Target: Interleukin receptor-associated kinases 1 and 4 (IRAK1/4)

Pre-clinical Phase 1 Phase 2 REGISTRATIONAL Approved
Pre-clinical Complete
Phase 1 Complete
Phase 2 Not Started
REGISTRATIONAL Not Started
Approved Not Started

KEY:

Company-sponsored Trials

1 Please see the TAVALISSE Full Prescribing Information

2 Please see the REZLIDHIA Full Prescribing Information, including Boxed WARNING

3 Please see the GAVRETO Full Prescribing Information, including Boxed WARNING

4 Please see the VEPPANU Full Prescribing Information

* Investigational compound - has not been submitted for approval by FDA

Note: Rigel also has partnerships with BerGenBio (bemcentinib) and Daiichi Sankyo (milademetan)